perindopril + moxonidine
Open-Label Non-Comparative Study of the Effects of a Combination Antihypertensive Treatment With Moxonidine + Perindopril in Hypertensive Patients With Metabolic Syndrome
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT04023565/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза IV — препарат уже зарегистрирован. Собирают дополнительные сведения о пользе и безопасности при обычном применении.
- Статус исследования в реестре не указан — уточняйте в центре.
- Возраст участников: 18–70 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 120 чел. во всех странах исследования.
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановая дата окончания (12.2020) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 12 · невключение: 17
Критерии включения
- Patients (male and female) aging 18 to 70 years.
- Grade 1, 2 AH (SBP 140-179 mm Hg and/or DBP 90-109 mm Hg according 2018 ESH/ESC guidelines)
- PWV > 10 m/s
- Previous two-component antihypertensive therapy (ACEi/ARB+ diuretic (HCTZ or indapamide) or ACEI/ARB + amlodipine) during at least 6 months prior to the study enrollment
- Metabolic syndrome diagnosed by the 2009 Russian Society of Cardiology (RSC) National Guidelines criteria
- THE MAIN SIGN: central (abdominal) obesity defined as waist circumference (WC) above 80 cm in women and above 94 cm in men.
- ADDITIONAL CRITERIA:
- i. - arterial hypertension (BP ≥ 130/85 mm Hg) ii. - high triglycerides (≥ 1.7 mmol/l) iii. - decreased HDL-cholesterol (<1.0 mmol/l for men; <1.2 mmol/l for women) iv. - increased LDL-cholesterol > 3.0 mmol/l v. - fasting hyperglycaemia (fasting plasma glucose ≥ 6.1 mmol/l) vi. - impaired glucose tolerance (plasma glucose at 2 hours after glucose load from ≥7.8 to ≤11.1 mmol/l)
- Metabolic syndrome is defined as presence of central obesity and two of the additional criteria.
- Body Mass Index (BMI) >30 kg/m2.
- For female patients with childbearing potential: negative pregnancy test and willingness to use reliable methods of contraception until the study treatment completion
- Voluntarily signed informed consent to participate in the study.
Критерии невключения
- Contraindications for using ACEi and imidazoline receptor agonists.
- Administration of perindopril or moxonidine during 6 months before the study onset.
- Metformin therapy for prophylaxis diabetes mellitus type 2 in patients with pre-diabetes, which had been started within 6 months before the study enrollment. (If a patient receives metformin for a long time, i.e., more than 6 months, he/she can be included in the study, and metformin discontinuation is not required).
- Statin and/or fibrate therapy started within 6 months before the study enrollment. (If a patient receives statins and/or fibrates for a long time, i.e., more than 6 months, he/she can be included in the study, and discontinuation of statins and fibrates is not required).
- Current diagnosis of unstable angina, acute and subacute myocardial infarction.
- Heart failure of any functional class.
- Grade 3 AH (≥ 180/110 mm Hg).
- Sinus bradycardia (heart rate ≤50/min).
- Type 1 or 2 diabetes mellitus.
- Severe comorbidities, including mental diseases.
- Acute conditions (infections, exacerbation of chronic diseases, injuries, surgical interventions).
- Alcohol abuse.
- Pregnancy and lactation.
- Serious renal dysfunction (Estimated Glomerular Filtration Rate (eGFR) by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) ≤30 ml/min/1.73 m2).
- Serious hepatic dysfunction
- Malignancies diagnosed and treated during the previous 5 years prior to study enrollment.
- Inability to understand the study and to give informed consent for participation in it.
Источник: ClinicalTrials.gov, NCT04023565 · запись обновлена в реестре 23 июля 2019.
Дизайн и результаты
Что измеряют — первичные конечные точки (3), вторичных — 6
- Change in Pulse wave velocity (PWV) — baseline and 24 weeks
- Change in Central Blood Pressure (BP) — baseline and 24 weeks
- Change in Reflected wave index — baseline and 24 weeks
Цель исследования
The aim of study is to assess the angioprotective effects of antihypertensive combination therapy with perindopril 10 mg and moxonidine 0.4-0.6 mg in patients with arterial hypertension, metabolic syndrome, and obesity, who had Pulse Wave Velocity (PWV) \> 10 m/s on the previously administered two-component combination antihypertensive therapy.
Open-label non-comparative prospective study for 24 week for each patient.
Где проходит
1 центр в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT04023565 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, сроки, число участников, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.